LeonaBio Stock
LeonaBio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark J. Litton
- Employees
- 19
- Market cap
- $21 M
- IPO
- 18/09/2020
- Web
- leonabio.com
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses…
LeonaBio stock: price history
1D
-1.7%
1W
-9.6%
1M
-23.4%
6M
-41.3%
YTD
-31.3%
1Y
+42.1%
2Y
+14.3%
5Y
-94.6%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~26% weaker price swings than usual
Ask the agents about LeonaBio
Analyst assessment of LeonaBio
PRICE TARGET LOW
US$15.00
CONSENSUS
US$17.50
MEDIAN
US$17.50
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
5
BUY
3
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 19/08/2026
LeonaBio stock metrics
P/E
-0.16
P/B
0.67
EV/EBITDA
0.21
RETURN ON EQUITY
-56.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.0%
FLOAT SHARES
2,681,764
AVG. DAILY VOLUME (30D)
358,399
Dividends & Stock splits
Comparable stocks
Frequently asked questions about LeonaBio stock
What does LeonaBio do?
LeonaBio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark J. Litton, the company employs around 19 people.
The IPO was on 18/09/2020; the stock trades on NASDAQ under the ticker LONA.
What do analysts say about LeonaBio stock?
8 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
The average price target is US$17.50, ranging from US$15.00 to US$20.00, with a median of US$17.50.
This is an external assessment, not a statement by Market Jury.
When does LeonaBio report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
Does LeonaBio pay a dividend?
No, LeonaBio currently does not pay a dividend.
Which stocks are comparable to LeonaBio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get LeonaBio stock analyzed?
Clicking "Analyze stock" lets five strategies assess LeonaBio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.